Lower Respiratory Tract Pathogens Analyzed by Breath Test
|
By LabMedica International staff writers Posted on 14 Jul 2015 |

Image: Thermal desorption/gas chromatography/time-of-flight mass spectrometry (TD/GC-MS) (Photo courtesy of Markes International).

Image: The Water’s GCT Premier benchtop orthogonal acceleration time-of-flight mass spectrometer (Photo courtesy of the University College Dublin).
Healthcare associated infections, including ventilator associated pneumonia, are difficult to diagnose and treat, and are associated with significant morbidity, mortality and cost.
Chemically analyzing breath volatile profiles that were associated with the presence of clinically relevant pathogens in the lower respiratory tract from patients in intensive care can reveal bacterial infection in ventilated patients at risk of developing pneumonia.
Scientists at the University of Manchester (UK) and their colleagues recruited patients undergoing invasive mechanical ventilation in an intensive care unit. Clinical details related to the patient diagnoses and investigations were recorded, including data related to physiology, radiology, microbiology as well as blood biochemistry and hematology. In addition serum was analyzed for the inflammatory cytokines interleukin (IL)-6, IL-10 and procalcitonin. Samples were collected from 54 patients and assent obtained for 46 consultees between January and July 2010.
A novel sampling apparatus was developed for the specific purpose of capturing volatiles from the distal intratracheal air of mechanically ventilated patients. Analysis of breath samples was performed by thermal desorption/gas chromatography/time-of-flight mass spectrometry (TD/GC-MS, Markes International; Llantrisant, UK), and the GCT Premier mass spectrometer, (Waters Corp; Manchester, UK). Samples were also cultured for pathogens.
The dominant factors affecting breath sample analysis were the individual breath profile and duration of intubation. When these were taken into account, clear separation was seen between breath profiles at each time point by the presence/absence of pathogens. The most commonly isolated pathogens were Haemophilus influenzae found in 12 samples from 10 patients and Staphylococcus aureus found in 18 samples from 10 patients. Thirty-one (67%) patients had negative respiratory and blood culture samples at baseline, and 20 (43%) remained culture-negative for the duration of the study, although only two of these were sampled on more than two occasions.
Compounds found to be lower in concentration in the breath of infected versus non-infected patients included ethanol, 2-methyl cyclopentanone, heptane, and N-cyclohexyl-N′(2-hydroxyethyl)thiourea, while those found in higher concentration included 3-carene, n-butyric acid 2-ethylhexyl ester , nonanal and 2,6,11,15-tetramethyl-hexadecane. Multivariate analysis showed none of the blood inflammatory biomarkers measured, procalcitonin, IL10, IL6, IL10/6 ratio, total white cell count, predicted the presence of lower respiratory tract pathogens.
The authors concluded that volatile metabolites in the breath of ventilated patients at high risk of developing ventilator associated pneumonia (VAP) show distinct patterns that enable the differentiation of patients with and without pathogens in the airway. The study was published in the April 2015 issue of the journal Thorax.
Related Links:
University of Manchester
Markes International
Waters Corp.
Chemically analyzing breath volatile profiles that were associated with the presence of clinically relevant pathogens in the lower respiratory tract from patients in intensive care can reveal bacterial infection in ventilated patients at risk of developing pneumonia.
Scientists at the University of Manchester (UK) and their colleagues recruited patients undergoing invasive mechanical ventilation in an intensive care unit. Clinical details related to the patient diagnoses and investigations were recorded, including data related to physiology, radiology, microbiology as well as blood biochemistry and hematology. In addition serum was analyzed for the inflammatory cytokines interleukin (IL)-6, IL-10 and procalcitonin. Samples were collected from 54 patients and assent obtained for 46 consultees between January and July 2010.
A novel sampling apparatus was developed for the specific purpose of capturing volatiles from the distal intratracheal air of mechanically ventilated patients. Analysis of breath samples was performed by thermal desorption/gas chromatography/time-of-flight mass spectrometry (TD/GC-MS, Markes International; Llantrisant, UK), and the GCT Premier mass spectrometer, (Waters Corp; Manchester, UK). Samples were also cultured for pathogens.
The dominant factors affecting breath sample analysis were the individual breath profile and duration of intubation. When these were taken into account, clear separation was seen between breath profiles at each time point by the presence/absence of pathogens. The most commonly isolated pathogens were Haemophilus influenzae found in 12 samples from 10 patients and Staphylococcus aureus found in 18 samples from 10 patients. Thirty-one (67%) patients had negative respiratory and blood culture samples at baseline, and 20 (43%) remained culture-negative for the duration of the study, although only two of these were sampled on more than two occasions.
Compounds found to be lower in concentration in the breath of infected versus non-infected patients included ethanol, 2-methyl cyclopentanone, heptane, and N-cyclohexyl-N′(2-hydroxyethyl)thiourea, while those found in higher concentration included 3-carene, n-butyric acid 2-ethylhexyl ester , nonanal and 2,6,11,15-tetramethyl-hexadecane. Multivariate analysis showed none of the blood inflammatory biomarkers measured, procalcitonin, IL10, IL6, IL10/6 ratio, total white cell count, predicted the presence of lower respiratory tract pathogens.
The authors concluded that volatile metabolites in the breath of ventilated patients at high risk of developing ventilator associated pneumonia (VAP) show distinct patterns that enable the differentiation of patients with and without pathogens in the airway. The study was published in the April 2015 issue of the journal Thorax.
Related Links:
University of Manchester
Markes International
Waters Corp.
Latest Clinical Chem. News
- New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
- Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
- Study Compares Analytical Performance of Quantitative Hepatitis B Surface Antigen Assays
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







